SCHEMBL3368036

SCHEMBL3368036

O=[N+]([O-])c1ccc(C=Cc2cccc(Cl)c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.73
FBP1 P09467 4/20 0.63
NFE2L2 Q16236 3/20 0.60
ALDH1A1 P00352 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
PTGS2 P35354 3/20 0.54
PTGS1 P23219 1/20 0.54
APP P05067 1/20 0.53
NPC1 O15118 1/20 0.53
MAPT P10636 1/20 0.53
RAB9A P51151 1/20 0.53
RELA Q04206 1/20 0.53
TRPV1 Q8NER1 1/20 0.51
MAOB P27338 2/20 0.50
VCP P55072 1/20 0.50
MAOA P21397 1/20 0.50
MEN1 O00255 1/20 0.50
GFER P55789 1/20 0.50
KMT2A Q03164 1/20 0.50
CHAT P28329 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3368024 1.00 CYP19A1 (0.73) CYP19A1FBP1NFE2L2ALDH1A1TDP1
SCHEMBL3366106 0.82 MAOB (0.68) CYP19A1FBP1PTGS2PTGS1APP
SCHEMBL8618370 0.82 MAOB (0.68) CYP19A1FBP1PTGS2PTGS1APP
SCHEMBL3366102 0.82 MAOB (0.68) CYP19A1FBP1PTGS2PTGS1APP
SCHEMBL9785918 0.81 CYP19A1 (0.75) CYP19A1FBP1NFE2L2ALDH1A1PTGS2
SCHEMBL9785917 0.81 CYP19A1 (0.75) CYP19A1FBP1NFE2L2ALDH1A1PTGS2
SCHEMBL28107131 0.81 ALDH1A1 (0.59) CYP19A1FBP1ALDH1A1TDP1PTGS2
SCHEMBL22624704 0.81 PELI1 (0.55) CYP19A1FBP1NFE2L2ALDH1A1TDP1
SCHEMBL11301074 0.80 CYP19A1 (0.93) CYP19A1FBP1NFE2L2ALDH1A1TDP1
SCHEMBL11301072 0.80 CYP19A1 (0.93) CYP19A1FBP1NFE2L2ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542969-B1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS HOFFMANN LA ROCHE (CH) 2010-03-03 EP disclosed
CN-100503562-C Pyrrolidone derivatives as MAOB inhibitors HOFFMANN LA ROCHE (CH) 2009-06-24 CN disclosed
US-7122562-B2 4-pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-17 US disclosed
US-20060122235-A1 Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide IDING HANS 2006-06-08 US disclosed
US-7037935-B2 4-Pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-05-02 US disclosed
CN-1681777-A Pyrrolidone derivatives as MAOB inhibitors HOFFMANN LA ROCHE (CH) 2005-10-12 CN disclosed
EP-1542969-A1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-22 EP disclosed
US-20040106650-A1 4-Pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. 2004-06-03 US disclosed
WO-2004026827-A1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106650-A1 4-Pyrrolidino-phenyl-benzyl ether derivatives MAOB, MAOA, COMT CYP19A1 280/4885FBP1 2289/4885NFE2L2 857/4885
US-20060122235-A1 Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide MAOA, MAOB, PNPO CYP19A1 291/4885FBP1 1468/4885NFE2L2 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.